Holen Sie sich die Stockscreener-App
2.19
0.45%
-0.01
Handel nachbörslich:
2.19
Schlusskurs vom Vortag:
$2.20
Offen:
$2.2099
24-Stunden-Volumen:
8,120
Relative Volume:
0.32
Marktkapitalisierung:
$201.87M
Einnahmen:
$47.04M
Nettoeinkommen (Verlust:
$-63.98M
KGV:
-2.7158
EPS:
-0.8064
Netto-Cashflow:
$-34.39M
1W Leistung:
+1.39%
1M Leistung:
-0.45%
6M Leistung:
+42.21%
1J Leistung:
-20.36%
1-Tages-Spanne:
$2.0616
$2.2099
1-Wochen-Bereich:
$2.0616
$2.2399
52-Wochen-Spanne:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Firmenname
Innate Pharma Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IPHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.19 | 199.06M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Eingeleitet | Goldman | Neutral |
Innate Pharma Adr Aktie (IPHA) Neueste Nachrichten
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India
Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
Innate Pharma shares retain Buy rating on long-term strategy - Investing.com
AZN Stock Price and Chart — LSE:AZN - TradingView
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Zacks Investment Research
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
Finanzdaten der Innate Pharma Adr-Aktie (IPHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):